Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Nektar Therapeutics (NKTR)
NASDAQ:NKTR
RESEARCH TOOLSreports
Holding NKTR?
Track your performance easily
Earnings Data
Report Date
Feb 27, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.14Last Year’s EPS
-0.22Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2018
|% Change Since: -35.04%
|Next Earnings Date:Aug 08, 2018
Earnings Call Sentiment|Positive
The earnings call highlighted significant advancements in Nektar's pipeline and strategic financial decisions, such as the sale of a manufacturing facility, which have bolstered the company's financial position. However, ongoing litigation and delays in study timelines present challenges. Overall, the positive aspects of the pipeline's progress and financial health outweigh the lowlights.Company Guidance
During the third quarter 2024 earnings call for Nektar Therapeutics, the company provided robust guidance on various aspects of its operations and future prospects. They highlighted significant advancements in their pipeline, particularly with their lead asset, rezpegaldesleukin (REZPEG), which targets autoimmune disorders such as atopic dermatitis and alopecia areata. The Phase IIb studies for REZPEG are progressing well, with enrollment on track for a top-line data readout in the first half of 2025 for atopic dermatitis and the second half for alopecia areata. The company anticipates extending its cash runway into the fourth quarter of 2026, bolstered by the recent $90 million divestiture of their PEGylation reagent manufacturing facility. Financial guidance was updated, with expected full-year revenue between $90 million and $95 million, and a net loss of $37 million reported for Q3. Additionally, Nektar is advancing preclinical programs like NKTR-0165, aiming for an IND submission in the second half of 2025, and exploring strategic collaborations for its IL-15 oncology program, NKTR-255.Progress in Advancing Pipeline
Significant progress made in advancing pipeline focused on immunology and inflammation, particularly with the Phase II studies for REZPEG.
Strategic Divestiture
Sale of commercial PEGylation reagent manufacturing facility for $90 million, extending cash runway into Q4 2026.
Positive Preclinical Data
Preclinical data for NKTR-0165 and NKTR-422 showing promising results in autoimmune diseases and inflammation resolution.
Strong Financial Position
Ended Q3 with $249 million in cash and investments, no debt, and expected year-end cash of $265 million.
---
NKTR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
NKTR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $1.37 | $1.40 | +2.19% |
| Aug 08, 2024 | $1.21 | $1.11 | -8.26% |
| May 09, 2024 | $1.60 | $1.76 | +10.00% |
| Mar 04, 2024 | $0.90 | $0.88 | -2.22% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Nektar Therapeutics (NKTR) report earnings?
Nektar Therapeutics (NKTR) is schdueled to report earning on Feb 27, 2025, TBA Not Confirmed.
What is Nektar Therapeutics (NKTR) earnings time?
Nektar Therapeutics (NKTR) earnings time is at Feb 27, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NKTR EPS forecast?
NKTR EPS forecast for the fiscal quarter 2024 (Q4) is -0.14.
---